This Week in Local History June 15, 2022 The Review Archives 1972: WWF stars injured in highway crash 1922: Mystery of disappearing bridegroom…

10 Years agoZellers closes to make way for WalmartThe Review, June 13, 2012 HAWKESBURY Although the community knew it was going to happen, it was still a bit of a shock to watch as the familiar Zellers sign was removed from the stores long-time location on Cameron Street on June 7. After weeks of sales advertising that everything must go, the store is finally resigning to its fate to be turned into a Walmart.

25 Years AgoFour WWF stars treated at HGH after highway crashThe Review, June 18, 1997 HAWKESBURY Four celebrity wrestlers from the World Wresting Federation were treated at Hawkesbury General Hospital, after being hurt on Sunday in a single-car accident near Pointe Fortune on Highway 40. The wrestlers Sydney Psycho Sid Eudy, Charles Flash Funk Scaggs, Philip Lafon, and Dwight Furnas were in a Lincoln Continental that was heading from Montreal to Ottawa when the driver lost control of the car while adjusting the sunroof. Furnas suffered the most serious injury, with an apparent broken shoulder blade.

50 Years AgoTwo killed in head-on Highway 34 crashThe Review, June 14, 1972 VANKLEEK HILL Two Vankleek Hill residents died in a head on collision on Highway 34 about two kilometres north of Vankleek Hill. Rejean Morin, 33, and Dolores Sauve were in a 1965 Pontiac that collided with a 1965 Chevrolet containing three people. Yvon and Lise Lalonde and Danielle Filion, occupants of the second car were seriously injured in the accident.

75 Years AgoRecord cattle entries for Lachute FairThe Review, June 12, 1947 LACHUTE The Lachute Spring Fair this week promises to be an outstanding event. Dairy cattle entries have broken previous records, with 191 head of Ayrshires, 125 Holsteins, 20 Canadian and 25 head of Dairy Shorthorns. In sheep, there are 207 head entered and 100 swine. There are 165 heavy horses and well over 100 light horses. A catalogue listing the entries will be available at the commencement of the fair.

100 Years AgoMystery of disappearing bridegroom solvedThe Review, June 16, 1922 GLEN SANDFIELD The mystery of what happened to John McKinnon, a young and well-to-do farmer who disappeared nine weeks ago the day before he was to be married has been solved. In a letter to his friend Harry Gordon, McKinnon gave a detailed explanation of the real cause of his sudden disappearance. The letter, which is dated in the Nipissing District, is now in the hands of the authorities, In Glen Sandfield, the girl he was to have wed sits weeping and waiting for him to come home, however McKinnon states in the letter that he will not be returning.

125 Years AgoDiphtheria health resolutions must be enforcedThe Review, June 18, 1897 VANKLEEK HILL It is to be hoped that the resolutions adopted at the meeting of the Board of Health on Wednesday will be rigidly enforced. Simply placing a placard on the door of a house in which there is diphtheria is not a sufficient safeguard, especially if the door of the house on which the placard is placed is kept open and the placard obscured. The Board of Health is our health protector and we expect and demand protection its power is unlimited.

Read the original here:

This Week in Local History June 15, 2022 The Review Archives 1972: WWF stars injured in highway crash 1922: Mystery of disappearing bridegroom...

Recombinant Bovine Growth Hormone – American Cancer Society

Recombinant bovine growth hormone (rBGH) is a synthetic (man-made) hormone that is marketed to dairy farmers to increase milk production in cows. It has been used in the United States since it was approved by the Food and Drug Administration (FDA) in 1993, but its use is not permitted in the European Union, Canada, and some other countries. This document summarizes what is known about the product and its potential effects on health.

The human form of growth hormone, also calledsomatotropin, is made by the pituitary gland. It promotes growth and cell replication. Bovine growth hormone (BGH), also known asbovinesomatotropin(BST) is the natural form of this hormone in cattle.

Recombinant bovine growth hormone (rBGH) or recombinant bovine somatotropin (rBST) refers to bovine growth hormone that is made in a lab using genetic technology. Some rBGH products on the market differ chemically from a cow's natural somatotropin by one amino acid. Both the natural and recombinant forms of the hormone stimulate a cow's milk production by increasing levels of another hormone known as insulin-like growth factor (IGF-1).

Concerns about possible health effects on humans from milk produced using rBGH have focused on 2 main issues.

First, does drinking milk from rBGH-treated cows increase blood levels of growth hormone or IGF-1 in consumers? If it does, would this be expected to have any health effects in people, including increasing the risk of cancer? Several scientific reviews have looked at these issues and are the main focus of this document.

Second, cows treated with rBGH tend to develop more udder infections (mastitis). These cows are given more antibiotics than cows not given rBGH. Does this increased use of antibiotics lead to more antibiotic-resistant bacteria, and is this a health concern for people? This remains a concern, but it has not been fully examined in humans.

Bovine growth hormone levels are not significantly higher in milk from rBGH-treated cows. On top of this, BGH is not active in humans, so even if it were absorbed from drinking milk, it wouldn't be expected to cause health effects.

Of greater concern is the fact that milk from rBGH-treated cows has higher levels of IGF-1, a hormone that normally helps some types of cells to grow. Several studies have found that IGF-1 levels at the high end of the normal range may influence the development of certain tumors. Some early studies found a relationship between blood levels of IGF-1 and the development ofprostate,breast,colorectal, and other cancers, but later studies have failed to confirm these reports or have found weaker relationships. While there may be a link between IGF-1 blood levels and cancer, the exact nature of this link remains unclear.

Some studies have shown that adults who drink milk have about 10% higher levels of IGF-1 in their blood than those who drink little or no milk. But this same finding has also been reported in people who drink soy milk. This suggests that the increase in IGF-1 may not be specific to cow's milk, and may be caused by protein, minerals, or some other factors in milk unrelated to rBGH. There have been no direct comparisons of IGF-1 levels in people who drink ordinary cow's milk vs. milk stimulated by rBGH.

At this time, it is not clear that drinking milk, produced with or without rBGH treatment, increases blood IGF-1 levels into a range that might be of concern regarding cancer risk or other health effects.

In the early 1990s, the FDA and other organizations looked at 3 questions regarding IGF-1 exposure from rBGH-treated milk. These were:

The available evidence can be summarized as follows:

At least 8 other national and international review committees have evaluated the evidence concerning potential health effects of rBGH on humans and dairy cows. These reviews (and the most recent year they convened) are listed below. Several of these reports document adverse effects on cows, including higher rates of mastitis, foot problems, and injection site reactions.

Although the use of rBGH is still approved in the United States, demand for the product has decreased in recent years. Many large grocery store chains no longer carry milk from cows treated with rBGH. A United States Department of Agriculture survey conducted in 2007 found that less than 1 in 5 cows (17%) were being injected with rBGH.

The available evidence shows that the use of rBGH can cause adverse health effects in cows. The evidence for potential harm to humans is inconclusive. It is not clear that drinking milk produced using rBGH significantly increases IGF-1 levels in humans or adds to the risk of developing cancer. More research is needed to help better address these concerns.

The increased use of antibiotics to treat rBGH-induced mastitis does promote the development of antibiotic-resistant bacteria, but the extent to which these are transmitted to humans is unclear.

The American Cancer Society (ACS) has no formal position regarding rBGH.

Go here to see the original:

Recombinant Bovine Growth Hormone - American Cancer Society

Official GenF20 Plus | Best Human Growth Hormone Releaser

The Enteric Absorption System contains 16 powerful ingredients, each playing an important role in stimulating your body to naturally increase your HGH levels, including:

Clinical studies have shown the arginine canas much as triple your HGH levels, even into old age. And it can also help improve your exercise performance for high-intensity, short duration work outs.

It increases fat burning, builds muscle tissue, boosts immunity, fights cancer, promotes healing, enhances male fertility, and more!

Your body doesnt naturally produce arginine; you must get it from your diet. So its an important addition to GenF20 Plus!

Its the amino acid used most by your body during times of stress, and its the key to metabolism andmaintenance of muscle, cell division, and cell growth. It increases energy and mental alertness.

Plus studies have shown that it boosts immunity, lowers cholesterol, lowers blood pressure, mitigates risk factors of arthritis, diabetes, heart disease, and more!

Its one of the key stimulatory agents thatencourages the pituitary gland to secrete HGH!It also has a calming effect on the brain and may play a role in the health of the prostate.

When lysine is taken in combination with arginine,its been shown to be ten times more effective than just taking arginine alone.It too is reported to boost immunity and improve genital function!

Tyrosine is used by the thyroid gland for the production of Thyroxine, another vital hormone shown in clinical studies to help reduce fatigue and depression, as well as regulate growth and metabolism!

In western herbal medicine, Astragalus is often used to enhance metabolism and digestion,strengthen the immune system and help wounds and injuries heal.It is also believed to help improve the function of the lung, adrenal glands and the gastrointestinal tract, increase metabolism, sweating, and reduce fatigue.

Deer antler velvet is a natural source of glucosamine, chondroitin and collagen. The body uses glucosamine to manufacture glycosaminoglycans that are found in cartilage tissue.

Deer antler velvet also contains male and female hormones, including Insulin-like growth factor I (IGF-1) a hormone thats produced in the liver as a response togrowth hormone stimulation,IGF-1 (somatomedin C).

GABA, or Gamma-Aminobutryic Acid, is a powerful amino acid that was first discovered in 1883 in Berlin. It is classified as a neurotransmitter, which means it helps nerve impulses cross the synapses (gaps) and communicate better and has a number of positive effects on the nervous system.In addition, GABA stimulates the production of Human Growth Hormone (HGH).

Benefits include increased immunity, accelerated healing, increased bone and lean and muscle mass, and mitigation of aging factors!

Colostrum contains IGF-1 (insulin like growth factors), which are actually products of HGH. IGF-1 is used to measure HGH production levels and its thought that IGF-1 is actuallyresponsible for the anti-aging effects of HGH.

Colostrum is a form of milk produced by the mammary glands of mammals in late pregnancy and the few days after giving birth. GenF20 Plus includes Bovine Colostrum, which is virtually identical to human colostrum and actually contains MORE of some of the most beneficial properties!

L-Valine is an amino acid and a branched-chain amino acid found in high concentration in the muscles. L-Valine cannot be made by the body, and must be acquired through food or dietary supplements. It has a stimulating effect and is needed for muscle metabolism, repair and growth of tissue and maintaining the nitrogen balance in the body. Since it is a branched-chain amino acid, it can be used as an energy source in the muscles, and in doing so preserves the use of glucose.

Itstimulates the pituitary gland to operate more effectivelyand increase the release of HGH. As well, its believed to help improve some conditions associated with aging, including poor muscle tone.

Its a purified extract from lecithin which acts as an excellent emulsifier, facilitating the absorption of the other nutrients included in GenF20 Plus.

Phosphatidyl Choline also emulsifies and breaks down fat deposits in the body, making it helpful in the mitigation of risk factors for gallstones, atherosclerosis, heart disease, and liver problems, depression, memory loss, and neurological disorders.

Studies have shown that Ornithine is about doubly effective as arginine, which as mentioned above, can as much astriple your HGH levels!Especially when used in combination with arginine, lysine, and glutamine, also included in GenF20 Plus

Required to transport glucose from the blood into the cells, chromium helps maintain glucose levels by enhancing insulin activity. And lower blood glucose levels canincrease the release of HGH!

Chromium also assists with weight control, helping you to maintain a healthy metabolism, increasing your energy, and reducing body fat!

Originally posted here:

Official GenF20 Plus | Best Human Growth Hormone Releaser

Top 10 Reasons Why You Need to Deadlift | BOXROX – BOXROX

There are many reasons why you need to deadlift. This simple exercise activates some of the largest muscle groups in your body and is perfectly transferrable to day-to-day life.

The Deadlift is a full body compound barbell exercise that involves lifting the weight from the floor to the standing position with the arms straight down by the sides or the body.

A good deadlift will help you build midline stability and teach you how to safely pick up objects from the floor.

Before we delve into the benefits of this fantastic exercise, learn how to perform a proper deadlift:

Read more: How to Deadlift

Strength training is known for being able to improve your mood, state of mind, and increase your confidence. As you increase your strength and lift heavier, this will only increase.

Deadlifts will strengthen your midline, which in return will improve your posture and give you core stability and strength.

Especially if you spend the majority of you day sitting down, deadlifts can help minimise the negative effects this can have on your posture.

One of the reasons why you need to deadlift is because the exercise isnt a highly-technical movement, which means anyone can do them. Young, old, trained, or a newbie, deadlifts are a great strength training exercise.

Improving your deadlift will translate to stronger lifts elsewhere. Whether its bench pressing, squatting, bent over rows, or anything in between will benefit from you doing more deadlifts.

You dont always have to chase the heaviest number, performing 8+ reps of deadlifts can help improve your cardiovascular health and induce more fat burn.

Deadlifting is one of the most functional strength exercises. This means, it has real life lifting applications and, as such, can help prevent injury.

If you deadlift you know how to pick heavy things up and build the strength required to do so.

This exercise will not only increase your grip strength but also your overall strength, which is a great reason why you need to deadlift more. As a compound movement, it works many of the biggest muscles in your body and can be used as a measure of overall strength.

If you perform deadlifts with good form, follow the right technique, and do them at a weight you are comfortable with, they are a safe exercise. They are very easy to bail out of as well when you feel your form deteriorating.

Deadlifts increase hormone production, which means more testosterone and growth hormone. This, in turn, means more muscle and strength.

Read more: How to Increase Testosterone Naturally

Deadlifts work nearly all the major muscle groups in your body, so instead of performing countless isolation exercises, you can work many muscles at once with the deadlift.

Excerpt from:

Top 10 Reasons Why You Need to Deadlift | BOXROX - BOXROX

New Phase 1b/2 Clinical Research Study with SynDevRx Drug Evexomostat (SDX-7320) Announced for Triple-Negative Breast Cancer Patients with Baseline…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--SynDevRx, Inc. today announced the opening of a first-of-its-kind Phase 1b/2 study for patients with triple-negative breast cancer and baseline insulin resistance, testing the novel study drug evexomostat (SDX-7320) in combination with standard-of-care treatment Halaven (eribulin, Esai). Evexomostat is among the first anti-cancer therapeutics being developed specifically for cancer patients with baseline metabolic dysfunction (obesity, type 2 diabetes and pre-diabetes). The clinical research study is being conducted in collaboration with New Yorks Memorial Sloan Kettering Cancer Center (MSK).

Insulin resistance, also known as hyperinsulinemia, is a condition that can go undetected until a patient develops overt type two diabetes mellitus (T2D) or elevated HbA1c. Insulin controls blood glucose levels but is also a potent growth hormone. It has been widely reported that high insulin levels in the presence of certain cancers, like breast cancer1, can cause the tumors to grow faster, become more difficult to treat and lead to premature cancer progression with worse patient outcomes2. The aim of this research study is to explore the impact of targeting insulin and improving insulin resistance in combination with standard-of-care therapy on patients treatment response and outcomes. It is the first prospective study using a clinical therapeutic designed specifically to address this critical, yet grossly understudied aspect of cancer progression.

Dr. Neil Iyengar, MD, an MSK breast medical oncologist and principal investigator of this study, has been at the forefront of researching the negative influences that dysregulated metabolic hormones, like insulin, play in cancer patients treatment outcomes.

Metabolic hormones play an important role in cancer establishment and progression, and are likely deterministic to patients clinical outcomes, Dr. Iyengar said. The area of metabo-oncology research, historically overlooked, has gained momentum over the past several years, and may soon emerge as an essential aspect of cancer treatment. It is known that a patients metabolic health status impacts survival after cancer diagnosis, and in some cases, how well and for how long cancer treatment is effective.

In a previous study, evexomostat (SDX-7320) demonstrated potent effects on elevated insulin levels in late-stage cancer patients, while preventing new metastases in several patients and with an acceptable safety profile, said Bradley Carver, co-founder and Chief Executive Officer of SynDevRx. While the focus of this clinical study is targeting insulin levels and the impacts on TNBC progression, the additional anti-angiogenic effects of evexomostat (SDX-7320) also seen in a phase 1 study may independently enhance clinical benefits for patients. Further, oncologists typically dont consider their patients metabolic health when designing treatment regimens. This study could change that. Dr. Iyengars trailblazing research and deep understanding of the metabo-oncology patient population, along with MSKs exceptional reputation for outstanding and innovative research is the perfect opportunity to showcase the multi-faceted effects of evexomostat (SDX-7320) for breast cancer patients, said Bradley Carver.

SynDevRx is at the forefront of metabo-oncology research and drug development, and we appreciate all the efforts from the team at MSK to bring this new experimental treatment paradigm to patients, Carver continued. Dr. Iyengars unique experience integrating patients metabolic health with their cancer treatment has resulted in a study design that we believe could lead to future clinical practices that incorporate patients insulin levels and overall metabolic health into their cancer treatment regimens.

SynDevRx is establishing global collaborations with leading research institutions focused on the downstream effects that obesity and dysregulated metabolic hormones have on cancer progression and metastasis. We invite other researchers to work with us as we untangle these complex and critical interactions between cancer and dysregulated metabolic hormones, said SynDevRxs co-founder and Chief Business Officer James Shanahan.

About Evexomostat (SDX-7320)

Evexomostat (SDX-7320) is among the first drugs being developed specifically for cancer patients with metabolic complications, such as obesity, diabetes, high blood glucose or HbA1c, pre-diabetes or insulin/leptin resistance. For certain tumor types, metabolic hormones stimulate oncogenic pathways, making the cancer more aggressive and deadlier. Evexomostat acts by binding irreversibly to its target enzyme MetAP2, triggering downstream improvements in the metabolic hormones insulin, leptin and adiponectin, regulation of key lipids, and inhibition of the important angiogenic proteins bFGF and VEGF-C, as was demonstrated in a Phase 1 clinical study in late-stage cancer patients. In preclinical studies, evexomostat also directly inhibited multiple cell cycle signaling pathways, provided synergistic anti-tumor effects in combination with a PI3K inhibitor, reduced angiogenesis, controlled aberrant metabolic hormone signaling, and reversed obesity-induced immune suppression within the tumor micro-environment of tumor-bearing obese mice. Evexomostat is being developed for use in combination with clinically indicated standard-of-care cancer therapies for breast and other tumor types.

About SynDevRx, Inc.

SynDevRx is a privately held clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. that is leading the research and development of treatments that address the interactions between cancer and dysregulated metabolic hormones. i.e., metabo-oncology. Obesity, pre-diabetes and type 2 diabetes are known to worsen certain cancer patients prognoses, but oncologists have no specific tools to treat systemic or treatment-induced metabolic complications, except for diet and exercise. SynDevRx is initiating a series of proof-of-concept clinical studies of its drug candidate evexomostat (SDX-7320) to show that improving these hormones together with effects on angiogenesis and the tumor micro-environment will result in better patient outcomes, thereby establishing a new and complementary treatment paradigm for tens of thousands of cancer patients. For more information visit http://www.syndevrx.com.

See the original post here:

New Phase 1b/2 Clinical Research Study with SynDevRx Drug Evexomostat (SDX-7320) Announced for Triple-Negative Breast Cancer Patients with Baseline...

North America Biosimilars Market is projected to grow at CAGR of 25.1% by 2030 The Greater Binghamton Business Journal – The Greater Binghamton…

North America Biosimilars Market report listed by Bonafide Research delivers a complete overview of key components like drivers, limitations, historic and current trends, technical development, and future growth. Research report contains company analysis, size, share, revenue and sales of the company, current advancements. North America Biosimilars Market analysis also focuses on the global key top industry players in the market, with details such as company profiles, capacity, production, price, cost, revenue.

North America biosimilars market is expected to grow by 25.1% annually in the forecast period and reach $27.57 billion by 2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.

Get a free sample report : https://www.bonafideresearch.com/samplereport/92001175/north-america-biosimilars-market

Highlighted with 29 tables and 54 figures, this 116-page report North America Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire North America biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects: Market Structure Growth Drivers Restraints and Challenges Emerging Product Trends & Market Opportunities Porters Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Country.

Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. Recombinant Non-glycosylated Biosimilars Insulin Recombinant Human Growth Hormone (rHGH) Granulocyte Colony Stimulating Factor Interferon Recombinant Glycosylated Biosimilars Monoclonal Antibodies (mAb) Erythropoietin (EPO) Follicle Stimulating Hormone Recombinant Peptides and Others Tumor Necrosis Factor (TNF)-Inhibitor Parathyroid Hormone Enzymes, Immunomodulators, GnRH Analogs and Others

Based on Indication, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. Cancer Autoimmune Disease Blood Disorder Diabetes Growth Hormone Deficiency Infectious Diseases Other Indications

Based on Manufacturing, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. Contract Manufacturing Inhouse Manufacturing

Based on End User, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. Hospitals and Clinics Research Institutes Other End Users

Geographically, the following national/local markets are fully investigated: U.S. Canada MexicoFor each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Product Type, Indication, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.Key Players (this may not be a complete list and extra companies can be added upon request):AMEGA Biotech S.A.Apotex Inc.Biocon LtdBiogen Inc.Boehringer IngelheimCelltrion, Inc.Dr. Reddys Laboratories Ltd.Eli Lilly and CompanyIntas Pharmaceuticals Ltd.LG Chem, Ltd.Merck and Co. Inc.Mylan N.V.Pfizer Inc.Samsung Biologics Co., Ltd.Sandoz International GmbHSTADA Arzneimittel AGTeva Pharmaceutical Industries Ltd.(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Key Indicators Analysed Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2020-2030 & Sales with a thorough analysis of the markets competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors. Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2020-2030 . Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications. Market Trends: Market key trends which include Increased Competition and Continuous Innovations. Opportunities and Drivers: Identifying the Growing Demands and New Technology Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Get full access of the report : https://www.bonafideresearch.com/product/92001175/north-america-biosimilars-market

CONTACT US:

Steven Thomas Sales & Marketing ManagerE-mail: sales@bonafideresearch.comAsia-Pacific: +91 7878231309Europe: +44 20 8089 0049North America: +1 201 793 8545https://www.bonafideresearch.com/

ABOUT US:

Bonafide Research is the fastest growing global market research and consulting company providing syndicated research reports, customized research reports, and consulting services to a range of verticals. They have been closely working with a wide client base ranging from Fortune 1000 companies to small and medium enterprises by helping them in tracking the constantly changing market scenario.

Bonafide has continuously made efforts to evolve and enhance the report quality with each passing day. Bonafide Research has a strong base of analysts and consultants from assorted areas of expertise who track the latest economic, demographic, trade and market data globally and help clients to make informed business decisions. They periodically update their market research studies to ensure that their clients get the most recent, relevant, actionable and valuable information for strategy development and to extract tangible results.

Read the rest here:

North America Biosimilars Market is projected to grow at CAGR of 25.1% by 2030 The Greater Binghamton Business Journal - The Greater Binghamton...

List of human hormones – Wikipedia

SNNameAbbr.TypeTissueCellsReceptorTarget TissueEffect1Adrenaline

(or epinephrine)

(or norepinephrine)

(or Islet Amyloid Polypeptide)

(or Mllerian-inhibiting factor/hormone)

(or corticotropin)

Angiotensin

release of aldosterone from adrenal cortexdipsogen.

(or vasopressin, arginine vasopressin)

(or atriopeptin)

reducing systemic vascular resistance,reducing blood water, sodium and fats

In male: spermatogenesis, enhances production of androgen-binding protein by the Sertoli cells of the testes

secretion of growth hormone from anterior pituitary gland

increases blood glucose level

Inhibit immune response, towards the human embryo.

increase insulin resistance and carbohydrate intolerance

Release Insulin-like growth factor 1 from liver

intake of lipids and synthesis of triglycerides in adipocytesOther anabolic effects

(or somatomedin)

regulate cell growth and development

In male: stimulates Leydig cell production of testosterone

(or pitocin)

Stimulates contraction of cervix and vagina. Involved in orgasm, trust between people,[2] and circadian homeostasis (body temperature, activity level, wakefulness).[3]

(Slightly) decrease blood phosphate:

(or leuteotropic hormone)

Enhances effects of cholecystokininStops production of gastric juice

(or growth hormoneinhibiting hormone or

growth hormone releaseinhibiting hormone or

somatotropin releaseinhibiting factor or somatotropin releaseinhibiting hormone)

Reduces smooth muscle contractions and blood flow within the intestine[4] Inhibit release of insulin from beta cells[5] Inhibit release of glucagon from alpha cells[5] Suppress the exocrine secretory action of pancreas.

(or thyrotropin)

Read more:

List of human hormones - Wikipedia

No observed benefit of adjuvant everolimus combined with endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2…

1. Disease-free survival did not differ significantly between patient groups and overall survival at 3 years was the same for both groups.

2. A higher percentage of patients receiving everolimus experienced grade 3 or worse adverse effects as compared to those receiving placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: In the first 10 years after treatment with endocrine therapy (ET), roughly 20% of patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer have disease recurrence. Resistance to ET is via a dysregulation of the phosphatidylinositol-3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway. Everolimus is an mTOR inhibitor, and its combination with ET has showed prolonged progression-free survival (PFS) in both advanced and metastatic hormone receptor-positive HER2-negative breast cancer. This study aimed to compare the outcomes on disease-free survival (DFS), overall survival (OS), and safety of everolimus with ET to placebo with ET in women who were hormone positive breast cancer, HER2 negative in the adjuvant setting. The overall 3-year DFS was not statistical different in the overall group and in the subgroups with tamoxifen or aromatase inhibitor (AI). There was no difference in OS at 3 years. The most common grade 3 or 4 AEs were oral mucositis, hypertriglyceridemia, elevated liver enzymes, fatigue, and hyperglycemia. A higher percentage of patients in the everolimus group experienced these AEs, compared to those in the placebo group. Treatment withdrawal due to AEs occurred in 35.3% of patients in the everolimus group as compared to 10.0% of those on placebo. There was one death due to everolimus treatment. Limitations to this study include the inclusion of both premenopausal and menopausal patients as the different biology between these patients may have introduced a confounding component to the analysis of ET subgroups. Overall, the use of everolimus in the adjuvant setting for treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer cannot be recommended.

Click to read the study in The Journal of Clinical Oncology

Relevant Reading: Everolimus in postmenopausal hormone-receptorpositive advanced breast cancer

In-Depth [randomized controlled trial]: This double-blind, international, multi-centre study randomly assigned 1,278 adult female patients in a 1:1 ratio to receive either everolimus (637 patients) or placebo (641 patients) in combination with ET treatment for 2 years. The patients were further stratified by the type of ET aromatase inhibitors (AIs) versus tamoxifen luteinizing hormone-releasing hormone agonists. Initially, 10mg of everolimus daily was provided as a starting dose, but due to toxicity was decreased to 5mg with flexibility to increase to 10mg. The overall 3-year DFS did not differ and was 88% (95% confidence interval (CI), 85-91%) for the everolimus group and 89% (95% CI, 86-91%) for the placebo group (hazard ratio (HR) = 0.95; 95% CI, 0.69-1.32). The DFS for patients on AI was 87% (95% CI, 82-90%) in the everolimus group and 91% (95% CI, 87-93%) in the placebo group (HR = 1.25, 95% CI, 0.83-1.90). For patients on tamoxifen treatment, DFS was 91% (95% CI, 86-94%) in the everolimus group and 86% (95% CI, 81-90%) in the placebo group (HR = 0.62, 95% CI, 0.37-1.06). There was no difference in OS at 3 years and both groups had 96% (95% CI, 94-98% for everolimus, and 95%CI, 94-97% for placebo). The hazard ratio was 1.09 (95% CI, 0.62-1.92). The majority of patients in each group had experienced an AE (98.1% of those on everolimus, and 96.5% of those on placebo) and the most common grade 3 or 4 AEs were mucositis, hypertriglyceridemia, elevated liver enzymes, fatigue, and hyperglycemia; these were all higher in the everolimus treatment group. Serious AEs occurred in 11.8% of those on everolimus, and 9.3% of those on placebo; 38.2% of patients on 10mg of everolimus experienced AEs grade 3 or worse compared to 15% of patients on placebo and 25.4% of patients on 5mg of everolimus had AEs grade 3 or worse, compared to 16.1% of those on placebo. Treatment withdrawal occurred in 35.3% of those in the everolimus groups and 10.0% of those in the placebo groups. One patient died secondary to everolimus treatment.

Image: PD

2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

See more here:

No observed benefit of adjuvant everolimus combined with endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2...

US HGH Biosimilars Market Share Analysis Of Key Market Participants And Their Competitive Landscape Zydus Cadila, Roche, Nanogen, Biosidus …

Overview Of HGH Biosimilars Market

Latest Update: This has brought along several changes this report also covers the impact of Current COVID-19 situation

The risingtechnology in HGH Biosimilars Marketis also depicted in thisresearchreport. HGH Biosimilars is DNA recombinant human growth hormone, which has the same function as human growth hormone. It can promote bone, visceral and whole body growth, promote protein synthesis, affect fat and mineral metabolism, and play a key role in human growth and development. Subcutaneous injection of about 80% was absorbed, 5 hours to reach the peak of blood drug concentration, the half-life of 4 hours. About 90% of the injection dose is metabolized in the liver. Only about 0.1% of the dose is excreted from the biliary tract and the kidneys. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail. The study considers the present scenario of the data center power market and its market dynamics for the period 2022-2028. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Get a Sample PDF copy of the report @ https://www.reportsinsights.com/sample/591770

Key Competitors of the Global HGH Biosimilars Market are: Johnson & Johnson, Gilead Sciences, Pacira, Sun Pharmaceutical, Luye Pharma, Sigma-Tau Group, Fudan-Zhangjiang, Teva Pharmaceutical, CSPC, Novartis, Kingond Pharm

Historical data available in the report elaborates on the development of the HGH Biosimilars on national, regional and international levels. HGH Biosimilars market Research Report presents a detailed analysis based on the thorough research of the overall market, particularly on questions that border on the market size, growth scenario, potential opportunities, operation landscape, trend analysis, and competitive analysis.

Major Product Types covered are: ClinicalExperiment

The Application Coverage in the Market are: TreamentPrevention

This study report on global HGH Biosimilars market throws light on the crucial trends and dynamics impacting the development of the market, including the restraints, drivers, and opportunities.

To get this report at a profitable rate.: https://www.reportsinsights.com/discount/591770

The fundamental purpose of HGH Biosimilars Market report is to provide a correct and strategic analysis of the HGH Biosimilars industry. The report scrutinizes each segment and sub-segments presents before you a 360-degree view of the said market.

Market Scenario:

The report further highlights the development trends in the global HGH Biosimilars market. Factors that are driving the market growth and fueling its segments are also analyzed in the report. The report also highlights on its applications, types, deployments, developments of this market.

Highlights following key factors:

:-Business descriptionA detailed description of the companys operations and business divisions.:-Corporate strategyAnalysts summarization of the companys business strategy.:-SWOT AnalysisA detailed analysis of the companys strengths, weakness, opportunities and threats.:-Company historyProgression of key events associated with the company.:-Major products and servicesA list of major products, services and brands of the company.:-Key competitorsA list of key competitors to the company.:-Important locations and subsidiariesA list and contact details of key locations and subsidiaries of the company.:-Detailed financial ratios for the past five yearsThe latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Our report offers:

Market share assessments for the regional and country level segments. Market share analysis of the top industry players. Strategic recommendations for the new entrants. Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets. Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations). Strategic recommendations in key business segments based on the market estimations. Competitive landscaping mapping the key common trends. Company profiling with detailed strategies, financials, and recent developments. Supply chain trends mapping the latest technological advancements.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.reportsinsights.com/industry-forecast/hgh-biosimilars-markets-growth-trends-591770

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

Email:[emailprotected]

Sales:[emailprotected]

Go here to read the rest:

US HGH Biosimilars Market Share Analysis Of Key Market Participants And Their Competitive Landscape Zydus Cadila, Roche, Nanogen, Biosidus ...

Bubble Gut {or Palumboism} What, Why & How to Stop HGH Belly

HGH (Human Growth Hormone)GutWhat is a Bubble Gut?

A Bubble Gut is the excessive stomach distension around the midsection causingbodybuildersto appear asthough they've got excess fat and heavy bloating around the gut. This trend has become even more pronounced over the last 5 years, with images of Mr. Olympia winner and runner up Phil Heath and Kai Greene, and even previous champions like Ronnie Coleman, showing signs of excessive stomach distension despite extremely low body fat.

This has led to many spectators or fans wondering what is causing the appearance of a gut on these athletes and why it has increased in recent years. The stomach distension is known in bodybuilding circles as HGH Gut,Insulin Gut, "Palumboism",or more popularly, Bodybuilder Belly, Muscle Gut or "Bubble Gut". As the above name suggests, the stomach distension seen in these bodybuilders is believed to be caused by insulin and human growth hormone (HGH) abuse.

To help you navigate this article, we've included a table of contents linking to each section:

What causes bubble gut in bodybuilders?

A Multi-Faceted Problem

How to prevent an HGH belly

Bubble gut is caused by factors such asincreased use of insulin andthe introduction of HGH injectionsuse in the nineties. There is no one factor that has been proven to cause the emergence of the bodybuilder belly (Palumboism). The most realistic explanation is a combination of factors.

These include:

The extremely high doses of HGH used by bodybuilders, estimated at around 5 milligrams per day, can cause side effects such as the excessive growth of some tissues, like the intestines. With larger intestines, the abdomen can bulge to up to twice its natural size, particularly after food consumption.

Many bodybuilders also combine HGH, and many other substances, with insulin use; a practice known as stacking. This insulin use can then cause increased fat storage behind the stomach, known as visceral fat, which can lead to a larger abdomen.

Through the use of insulin and Human Growth Hormone drugs and the addition of multiple supplements and a diet that is extremely high in protein, muscle mass increases considerably. This causes not only an increase in mass in the Rectus Abdominis, or the six pack, itself, but also in the muscles that lie underneath it, such as the Transverse Abdominus and the Internal Obliques. This causes the entire midsection to grow and protrude, giving a blocky appearance and contributing to stomach distension. The 'look' has been nicknamed 'Palumboism'.

High carbohydrate foods cause an increase in glycogen to be stored in the muscles which causes increased water retention, as glycogen attracts water. Both this and the large volume of carbohydrate rich foods further contribute to Muscle Gut by providing a 'bloated' look.

Irrespective of protein, carbohydrates or supplements, all bodybuilders follow an extremely high calorie diet, with some consuming over 10,000 calories per day. This high calorie food intake also means a high volume of food which can stay in the stomach for prolonged periods causing gut distension.

Many bodybuilders and fitness models use a technique known as 'carb' or 'glyco' loading, where a bodybuilder dehydrates and lowers carbohydrate intake and, in many cases, ingests diuretics to help flush water out of the body. They then ingest large amounts of carbohydrates and water to cause a supercompensation of water content in the muscles, allowing greater definition and muscle volume. However, if mistimed, this loss of water, along with the problems of high carbohydrate intake, can cause slower digestion and stomach emptying, meaning more food stays in the gut for longer, promoting distension.

Any combination of the above factors can lead to gut distension and explains the names given to this condition by the bodybuilding community. While no studies have proven these theories directly, there is scientific evidence that all of the above mechanisms behind HGH gut are possible (1, 2).

Due to recent studies showing a lack of effectiveness in human growth hormone promoting strength or muscle mass (3, 4), and the dangers of insulin abuse compared to similar benefits elicited from safer supplements (5, 6), abstinence would seem like a natural solution. However, the reason most of these bodybuilders take high levels of these drugs is due both to the perceived benefit they possess for aiding muscle growth, and because they can aid tendon recovery and growth and prevent injury (7). As such, there is little point in recommending completely halting their use. However, there may be methods to reduce stomach distension without stopping or even reducing HGH or insulin use. There are a number of methods that could be used to help prevent the Insulin or HGH Gut from occurring in new bodybuilder as well as help reduce its appearance in veteran athletes.

From examining bodybuilders who were known to have used HGH throughout their careers (i.e. Dorian Yates and Ronnie Coleman), its clear that stomach distension isnt permanent and is reversible by lowering the dose or eliminating use (ending the cycle). Insulin is also primarily bulking substance and can actually hinder the cutting process by increasing fat storage (8). So, reducing the amount of HGH and Insulin taken when cutting and approaching contests will allow a bodybuilder to reap all the benefits of the two drugs while reducing gut distension on stage.

Intermittent Fasting has been shown to be just as effective as conventional calorie cutting for helping weight and fat loss while maintaining muscle (9, 10). When timed correctly, this can ensure that the amount of food in the digestive system is low and help reduce any stomach distension while allowing a high quality physique to be maintained during a contest.

Many bodybuilders are tempted to increase their carbohydrate intake when cutting to maintain muscle mass. However, as insulin use has been reduced or eliminated, their is no additional benefit to maintaining high carbohydrate intake. In fact, cutting carbohydrates and maintaining fats can cause higher levels of testosterone when dieting (11), while the decreased food volume will help keep Muscle Gut under control. During these periods, protein intake can be kept high without high carbohydrate dairy products by using meat, eggs and supplements like Grenade Carb Killa Protein BarsTM for high protein and fibre or low carbohydrate whey isolate shakes like Isotean TM protein. It should also be noted that increasing protein further during these diets could help improve visceral fat loss that was caused by the previous insulin use. Also, eating out at certain restaurants or meals can be challenging when looking to maintain a low-carb diet. For this, consider consulting this guide on low-carb meals and restaurants that are available.

When using water manipulation techniques, ensure that sodium and electrolyte intake is increased through supplementing with electrolyte solutions such as Genius Electrolytes, and that fibre and digestive enzyme intake is high to aid digestion. This can be done by supplementing with digestive aids like Fiberlyze. Also make sure that timing is correct, giving approximately 24 hours to allow full glycogen supercompensation before contest time. All of these strategies can be effective in reducing Bodybuilder Belly and improving physique on stage. However, it is important to consider individual differences and experiment with these steps carefully, as responses to them may differ between individuals. Also, it can be difficult to maintain strict dietary protocols when travelling for competition. So, check out this guide on dieting while on the road to help consider different foods and diets while on the road can help a lot.

About the Author

Reggie Johal is the founder of Predator Nutrition, a UK based health and supplement store. Reggie owes much of his extensive strength and fitness knowledge to his former career as a Great Britain American Footballer.

Read the original post:

Bubble Gut {or Palumboism} What, Why & How to Stop HGH Belly